Assignee
ABBVIE STEMCENTRX LLC
US·30 granted patents·27 pending applications·161 citations·filing 2014–2025
Top patents by PatentIndex Score
57 records- 0198US11033634B2Light chain variable regionsABBVIE STEMCENTRX LLC·Filed 2019·Granted Jun 15, 2021·6 cites·16 claims
- 0296US9937268B2Anti-DLL3 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Granted Apr 10, 2018·9 cites·30 claims
- 0396US9931421B2Methods of delivering DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Apr 3, 2018·9 cites·30 claims
- 0496US9931420B2Methods of making DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Apr 3, 2018·9 cites·30 claims
- 0596US9878053B2Methods of delivering DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 30, 2018·9 cites·30 claims
- 0696US9867887B1Anti-DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 16, 2018·9 cites·30 claims
- 0796US9861708B2Kits containing DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 9, 2018·9 cites·30 claims
- 0896US9855343B2Anti-DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 2, 2018·9 cites·30 claims
- 0996US9775916B1Anti-DLL3 antibody drug conjugates for treating cancerABBVIE STEMCENTRX LLC·Filed 2017·Granted Oct 3, 2017·9 cites·30 claims
- 1096US9770518B1Anti-DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Sep 26, 2017·9 cites·30 claims
- 1196US9764042B1Methods of making DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Sep 19, 2017·9 cites·30 claims
- 1295US10137204B2Anti-DLL3 antibody drug conjugates for treating cancerABBVIE STEMCENTRX LLC·Filed 2016·Granted Nov 27, 2018·8 cites·33 claims
- 1390US10478509B2Anti-DLL3 antibody drug conjugates for treating cancerABBVIE STEMCENTRX LLC·Filed 2018·Granted Nov 19, 2019·6 cites·30 claims
- 1489US10836831B2Anti-PTK7 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Granted Nov 17, 2020·3 cites·23 claims
- 1585US10035853B2Site-specific antibody conjugation methods and compositionsABBVIE STEMCENTRX LLC·Filed 2016·Granted Jul 31, 2018·13 cites·42 claims
- 1683US10308721B2Anti-DLL3 antibodies and drug conjugates for use in melanomaABBVIE STEMCENTRX LLC·Filed 2015·Granted Jun 4, 2019·7 cites·28 claims
- 1782US9914784B2PTK7 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Granted Mar 13, 2018·3 cites·19 claims
- 1880US10934359B2Anti-BMPR1B antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Granted Mar 2, 2021·3 cites·9 claims
- 1980US10053511B2Anti-claudin antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2014·Granted Aug 21, 2018·5 cites·55 claims
- 2080US9993566B2SEZ6 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2014·Granted Jun 12, 2018·4 cites·41 claims
- 2178US10047163B2Multispecific constructsABBVIE STEMCENTRX LLC·Filed 2014·Granted Aug 14, 2018·3 cites·3 claims
- 2277US10533051B2Anti SEZ6 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 14, 2020·1 cites·17 claims
- 2377US9968687B2Anti-DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2014·Granted May 15, 2018·2 cites·59 claims
- 2477US2019247510A1Dll3 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2019·Application pending·0 cites
- 2576US10428156B2Anti-MFI2 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2015·Granted Oct 1, 2019·3 cites·32 claims
- 2675US10017565B2Modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Granted Jul 10, 2018·2 cites·19 claims
- 2775US2019046656A1Dll3 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Application pending·0 cites
- 2872US2025213714A1Anti-sez6 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2025·Application pending·0 cites
- 2971US10189910B2Anti-DPEP3 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Granted Jan 29, 2019·1 cites·38 claims
- 3071US9777071B2Anti-DPEP3 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Granted Oct 3, 2017·1 cites·15 claims
- 3169US2021338831A1Anti-sez6 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2021·Application pending·0 cites
- 3268US11077203B2Anti-SEZ6 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2020·Granted Aug 3, 2021·0 cites·4 claims
- 3368US2021196834A1Anti-sez6 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2019·Application pending·0 cites
- 3467US2020181256A1Anti sez6 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2019·Application pending·0 cites
- 3559US2018237512A1Novel modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Application pending·0 cites
- 3658US9969798B2Modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Granted May 15, 2018·0 cites·27 claims
- 3754US2021261670A1Novel anti-bmpr1b antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2021·Application pending·0 cites
- 3853US2018067120A1Identification and enrichment of cell subpopulationsABBVIE STEMCENTRX LLC·Filed 2017·Application pending·0 cites
- 3952US2019225685A1Anti-dll3 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2019·Application pending·0 cites
- 4050US10087258B2Anti-CD324 monoclonal antibodies and uses thereofABBVIE STEMCENTRX LLC·Filed 2016·Granted Oct 2, 2018·0 cites·8 claims
- 4149US2019077876A1Novel anti-claudin antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Application pending·0 cites
- 4249US2019022241A1Novel sez6 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Application pending·0 cites
- 4344US2019201542A1Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transitionABBVIE STEMCENTRX LLC·Filed 2017·Application pending·0 cites
- 4443US2018346565A1Site-specific antibody conjugation methods and compositionsABBVIE STEMCENTRX LLC·Filed 2018·Application pending·0 cites
- 4542US2018243435A1Anti-dll3 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Application pending·0 cites
- 4641US2019016812A1Novel anti-tnfsf9 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Application pending·0 cites
- 4738US2019194319A1Anti-ascl1 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Application pending·0 cites
- 4837US2019127476A1Novel anti-tnfrsf21 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Application pending·0 cites
- 4937US2018112004A1Engineered site-specific antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Application pending·0 cites
- 5037US2019083645A1Novel anti-claudin antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →